Alnylam Pharmaceuticals Inc
ALNY328.160USD
-3.080-0.93%
종가 02/06, 16:00（ET）시세는 15분 지연됩니다
43.25B시가총액
1010.56P/E TTM
자세한 내용은 Alnylam Pharmaceuticals Inc 회사
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Alnylam Pharmaceuticals Inc 정보
종목 코드 ALNY
회사 이름Alnylam Pharmaceuticals Inc
상장일May 28, 2004
CEOGreenstreet (Yvonne L)
직원 수2230
유형Ordinary Share
회계 연도 종료May 28
주소675 W Kendall St
도시CAMBRIDGE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호02142-1168
전화16175518200
웹사이트https://www.alnylam.com/
종목 코드 ALNY
상장일May 28, 2004
CEOGreenstreet (Yvonne L)
Alnylam Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
Mr. Peter N. Kellogg
Mr. Peter N. Kellogg
Independent Director
Independent Director
775.00
+775.00%
Mr. David E. I. Pyott, CBE
Mr. David E. I. Pyott, CBE
Independent Director
Independent Director
--
--
Ms. Amy W. Schulman, J.D.
Ms. Amy W. Schulman, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Pushkal P. Garg, M.D.
Dr. Pushkal P. Garg, M.D.
Executive Vice President, Chief Research and Development Officer
Executive Vice President, Chief Research and Development Officer
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Yvonne L. Greenstreet, M.D.
Dr. Yvonne L. Greenstreet, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
78.82K
+9426.00%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
57.52K
+3413.00%
Mr. Tolga Tanguler
Mr. Tolga Tanguler
Chief Commercial Officer
Chief Commercial Officer
29.73K
+2290.00%
Dr. Dennis A. Ausiello, M.D.
Dr. Dennis A. Ausiello, M.D.
Independent Director
Independent Director
4.41K
--
Dr. Margaret A. Hamburg, M.D.
Dr. Margaret A. Hamburg, M.D.
Independent Director
Independent Director
911.00
+775.00%
Dr. Olivier Brandicourt, M.D.
Dr. Olivier Brandicourt, M.D.
Independent Director
Independent Director
775.00
+775.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
사업별USD
이름
수익
비율
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
기타
61.62M
4.93%
지역별USD
이름
수익
비율
United States
613.98M
49.16%
Net revenues from collaborations
351.74M
28.16%
Europe
172.67M
13.82%
Rest of World
64.43M
5.16%
Royalty revenue
46.20M
3.70%
사업별
지역별
사업별USD
이름
수익
비율
AMVUTTRA
685.30M
54.87%
Regeneron Pharmaceuticals
326.60M
26.15%
GIVLAARI
73.87M
5.91%
OXLUMO
52.83M
4.23%
Other
48.80M
3.91%
기타
61.62M
4.93%
주식 보유 통계
마지막 업데이트: Sat, Feb 7
마지막 업데이트: Sat, Feb 7
주주
주주 유형
주주
주주
비율
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
기타
54.86%
주주
주주
비율
Capital World Investors
12.44%
Fidelity Management & Research Company LLC
12.04%
The Vanguard Group, Inc.
10.21%
Capital Research Global Investors
5.47%
BlackRock Institutional Trust Company, N.A.
4.98%
기타
54.86%
주주 유형
주주
비율
Investment Advisor
69.40%
Investment Advisor/Hedge Fund
23.28%
Hedge Fund
3.81%
Research Firm
2.50%
Sovereign Wealth Fund
1.70%
Pension Fund
1.30%
Bank and Trust
1.26%
Individual Investor
0.43%
Private Equity
0.23%
기관 주식 보유
마지막 업데이트: Mon, Dec 8
마지막 업데이트: Mon, Dec 8
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
1525
136.86M
103.59%
+1.39M
2025Q3
1468
132.43M
102.39%
+2.53M
2025Q2
1335
129.81M
101.55%
+2.82M
2025Q1
1292
127.17M
99.72%
-2.77M
2024Q4
1248
125.34M
101.87%
-989.05K
2024Q3
1210
126.51M
99.20%
+3.13M
2024Q2
1165
122.70M
94.98%
+5.27M
2024Q1
1152
117.38M
97.56%
-6.00M
2023Q4
1149
120.10M
100.10%
-712.55K
2023Q3
1103
121.13M
101.32%
-503.11K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital World Investors
16.43M
12.44%
-370.75K
-2.21%
Sep 30, 2025
Fidelity Management & Research Company LLC
15.91M
12.04%
+854.66K
+5.68%
Sep 30, 2025
The Vanguard Group, Inc.
13.51M
10.22%
+267.08K
+2.02%
Sep 30, 2025
Capital Research Global Investors
7.22M
5.47%
+31.18K
+0.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
6.59M
4.98%
+52.87K
+0.81%
Sep 30, 2025
JP Morgan Asset Management
3.87M
2.93%
+2.07M
+115.83%
Sep 30, 2025
State Street Investment Management (US)
3.08M
2.33%
-91.63K
-2.89%
Sep 30, 2025
Baillie Gifford & Co.
2.79M
2.11%
-242.53K
-8.00%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.50M
1.89%
+100.47K
+4.19%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Tue, Dec 2
마지막 업데이트: Tue, Dec 2
이름
비율
Global X Genomics & Biotechnology ETF
6.48%
ProShares Ultra Nasdaq Biotechnology
5.81%
Invesco Nasdaq Biotechnology ETF
5.77%
Franklin Genomic Advancements ETF
5.35%
iShares Biotechnology ETF
5.07%
VanEck Biotech ETF
4.56%
American Century Focused Dynamic Growth ETF
3.76%
Goldman Sachs Future Health Care Equity ETF
3.42%
First Trust NYSE Arca Biotechnology Index Fund
3.33%
Invesco NASDAQ Next Gen 100 ETF
3.28%
더 보기
Global X Genomics & Biotechnology ETF
비율6.48%
ProShares Ultra Nasdaq Biotechnology
비율5.81%
Invesco Nasdaq Biotechnology ETF
비율5.77%
Franklin Genomic Advancements ETF
비율5.35%
iShares Biotechnology ETF
비율5.07%
VanEck Biotech ETF
비율4.56%
American Century Focused Dynamic Growth ETF
비율3.76%
Goldman Sachs Future Health Care Equity ETF
비율3.42%
First Trust NYSE Arca Biotechnology Index Fund
비율3.33%
Invesco NASDAQ Next Gen 100 ETF
비율3.28%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
